Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib

This study has been completed.
Sponsor:
Collaborator:
Bayer
Information provided by:
Helsinki University
ClinicalTrials.gov Identifier:
NCT00117299
First received: June 30, 2005
Last updated: May 25, 2010
Last verified: May 2010

June 30, 2005
May 25, 2010
September 2004
September 2007   (final data collection date for primary outcome measure)
Response rate [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Response rate
  • Adverse events
Complete list of historical versions of study NCT00117299 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
A Phase II, Open-Label Study of PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors (GISTs) Resistant to Imatinib Mesylate

This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec). The study participants are required to have histologically confirmed GIST with prior imatinib treatment for metastatic GIST. is administered orally 1250 mg/day. Six patients will first enter the study. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol in two stages (a maximum of 45 patients will be entered). Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.

This is an open-label, phase II study of PTK787/ZK222584 designed to determine the safety and efficacy of PTK787/ZK222584 in the treatment of imatinib-resistant GIST. The PTK787/ZK222584 dose used is 1250 mg daily. Six patients will first enter the study using a two-stage approach. If clinical benefit is obtained in >1 of 6 patients, 9 and 30 additional patients will be entered into the protocol (a maximum total number of 45 patients will be entered). Clinical benefit is defined as the occurrence of one or more of the following 3 measures: 1) objective response to PTK787 (a confirmed or unconfirmed partial response [PR] or a complete response [CR]); 2) metabolic response defined as >50% decrease in the standardized uptake value (SUV) of FDG uptake in >1 FDG-avid lesions in one or more of the patients; or 3) stabilized disease for 3 months or longer accompanied by symptomatic or performance status improvement. Medical history, current medical conditions, weight, height, and an electrocardiogram are recorded prior to the study entry. Other baseline examinations include a chest X-ray, hematologic tests, a coagulation panel, serum chemistries, urine analysis, a serum pregnancy test and a radiological assessment of the tumor. Tumor response is monitored with imaging at 4- to 8-week intervals. Hematological tests and serum chemistries are evaluated at 1- to 4-week intervals, and adverse events are collected continuously. Research blood tests are collected at the times of tumor evaluations. Dose adjustments are carried out as per the protocol. Patients who benefit from the study treatment will be treated with PTK787/ZK222584 until treatment failure.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Sarcoma
Drug: PTK787/ZK222584
PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
Other Name: vatalanib
Experimental: A
PTK/ZK o.d. 1250 mg p.o.
Intervention: Drug: PTK787/ZK222584
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
January 2009
September 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with histologically confirmed GIST
  • Imatinib resistance (primary resistance with progression, or progression after initial response). Resistance is defined as objective evidence of progression after at least 4 weeks of treatment with imatinib.
  • Imatinib therapy has been interrupted >7 days before study entry
  • Metastatic disease confirmed histologically, cytologically or radiologically
  • Presence of measurable tumor lesions as determined by RECIST criteria
  • Age 18 years or older
  • WHO performance status of 2 or less
  • Blood neutrophil count (ANC) 1.5 x 10^9/L or higher
  • Platelet count 100 x 10^9/L or higher
  • Serum bilirubin 1.5 x ULN (upper limit of normal) or less
  • Serum creatinine 2.0 x ULN or less
  • Written informed consent obtained according to local guidelines

Exclusion Criteria:

  • Patients who have received chemotherapy less than 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
  • Patients who have received a cumulative dose of doxorubicin >450 mg/m2 or epirubicin 800 mg/m2
  • Patients who have received immunotherapy within 2 weeks or who have not recovered from side effects of such therapy
  • Patients who have received radiotherapy within 2 weeks or who have not recovered from side effects of such therapy
  • Major surgery within 2 weeks prior to entry into this study or patients who have not recovered from side effects of such therapy
  • Patients who have received investigational drugs within 4 weeks prior to entry into this study or who have not recovered from side effects of such therapy
  • Patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control
  • Concurrent severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months, poorly controlled hypertension, history of labile hypertension, history of poor compliance with antihypertensive regimen, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
  • Acute or chronic liver disease (e.g., hepatitis, cirrhosis)
  • Confirmed diagnosis of HIV infection
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of PTK787/ZK222584 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the capsules/tablets)
  • Patients who are taking Coumadin (warfarin sodium); heparin is acceptable.
  • Patients unwilling to, or unable to, comply with the protocol
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Finland
 
NCT00117299
CPTK787 A2401/300267, GIST PTK787/ZK222584
No
Heikki Joensuu, Helsinki University central Hospital
Helsinki University
Bayer
Principal Investigator: Heikki Joensuu, M.D. Department of Oncology, Helsinki University Central Hospital
Helsinki University
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP